Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination

Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination

Bibliographic Details
Main Authors:	Sharma SK, Pokorski J, Finn MG, Jacqueline J, Rakasz E, Burton D, Wyatt R
Format:	Article
Language:	English
Published:	BMC 2012-09-01
Series:	Retrovirology

Similar Items

HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
by: Laurent Verkoczy, et al.
Published: (2014-05-01)

Neutralizing Antibodies Targeting HIV-1 gp41
by: Christophe Caillat, et al.
Published: (2020-10-01)

Structural studies on the anti-HIV1-gp 41 antibody, 1583
by: Beauchamp, Jeremy
Published: (1994)

Identification of HIV gp41-specific antibodies that mediate killing of infected cells.
by: Katherine L Williams, et al.
Published: (2019-02-01)

Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies
by: Christophe Caillat, et al.
Published: (2021-04-01)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
by: Han D, et al.
Published: (2012-09-01)

Diversification of specificity after maturation of the antibody response to the HIV gp41 epitope ELDKWA.
by: Henry N White, et al.
Published: (2012-01-01)

DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains
by: Scott JK, et al.
Published: (2012-09-01)

Anti-idiotypic antibody Ab2/3H6 mimicking gp41: a potential HIV-1 vaccine?
by: Kunert Renate, et al.
Published: (2011-11-01)

Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
by: Ling Ye, et al.
Published: (2011-01-01)

Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
by: Constantinos Kurt Wibmer, et al.
Published: (2017-01-01)

Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes
by: Nika M. Strokappe, et al.
Published: (2019-06-01)

Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity
by: Zheng Yang, et al.
Published: (2018-11-01)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
by: Reichart T, et al.
Published: (2012-09-01)

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates
by: Gao G, et al.
Published: (2012-09-01)

Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
by: Mei-Yun Zhang, et al.
Published: (2012-01-01)

Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein.
by: Vinita R Joshi, et al.
Published: (2020-05-01)

Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41.
by: S Moses Dennison, et al.
Published: (2011-01-01)

Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization.
by: Arthur S Kim, et al.
Published: (2014-07-01)

Elicitation of antibody responses against the HIV-1 gp41 Membrane Proximal External Region (MPER)
by: Cheng, Yuxing
Published: (2014)

Identification of variant HIV envelope proteins with enhanced affinities for precursors to anti-gp41 broadly neutralizing antibodies.
by: Hong Zhu, et al.
Published: (2019-01-01)

Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
by: Javier Guenaga, et al.
Published: (2012-01-01)

Cross-reactive Anti-gp41 HIV-1 Neutralizing Human Monoclonal Antibodies Selected by Competitive Panning Against gp140 – an Update
by: Sidorov Igor, et al.
Published: (2005-12-01)

The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects
by: Huan Liu, et al.
Published: (2018-04-01)

HIV-1 subtype C gp41-based synthetic peptide constructs as potential vaccine components
by: Philippeos, Christina
Published: (2009)

Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.
by: Ben-Jiang Ma, et al.
Published: (2011-09-01)

Properties of the C-terminal tail of HIV-1 gp41
by: Hollier, Mark John
Published: (2004)

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection
by: Xinling Wang, et al.
Published: (2021-03-01)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
by: Jing Pu, et al.
Published: (2019-08-01)

Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection
by: Naveen K. Vaidya, et al.
Published: (2018-06-01)

HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies.
by: Ji Wang, et al.
Published: (2011-03-01)

HIV-1 gp41 Fusion Intermediate: A Target for HIV Therapeutics
by: Chungen Pan, et al.
Published: (2010-02-01)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
by: Seth H. Pincus, et al.
Published: (2021-07-01)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
by: Caffrey Michael, et al.
Published: (2004-03-01)

Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.
by: Kristen M Kahle, et al.
Published: (2009-11-01)

Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations.
by: John M Louis, et al.
Published: (2014-01-01)

Membrane topology analysis of HIV-1 envelope glycoprotein gp41
by: Xiao Dan, et al.
Published: (2010-11-01)

Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost study.
by: Alexander Mader, et al.
Published: (2012-01-01)

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.
by: Mukta D Khasnis, et al.
Published: (2016-12-01)

Prevalence of antibodies against an immunodominant region of the HIV-1 envelope glycoprotein gp41 in sera from HIV-1 infected individuals in Brazil
by: Vera Bongertz, et al.
Published: (1994-09-01)